Market LIVE
Published markets; coverage varies by country
Product profile · United States

PARICALCITOL

 ·  Patent Litigation & Settlement History ↓

IngredientPARICALCITOL
Application typeNDA
Application201657
Product003
Dosage formSOLUTION
RouteINTRAVENOUS
Strength0.01MG/2ML (0.005MG/ML)
Approval date2014-10-21
Marketing statusWITHDRAWN
Status event2026-04-08
ApplicantHOSPIRA
Product source

Current GenericRadar decision

Year2026
SelectionWITHDRAWN
ReviewFINAL
Anchor typeFDA_APPROVAL_WITHDRAWAL
Anchor date2026-04-08
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event2026-04-08

FDA approval of this entire NDA and its strengths was withdrawn effective 2026-04-08. This legal notice supersedes the discontinued-list classification. Rereview corrected Discontinued to WITHDRAWN and recorded the actual FDA effective date. The notice publication date is not substituted for a later effective date.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-11 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
091108 / 003FINAL_APPROVAL · FINAL_APPROVED2011-07-27—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
204910 / 003FINAL_APPROVAL · FINAL_APPROVED2016-08-17—CAPLIN STERILES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
206699 / 003FINAL_APPROVAL · FINAL_APPROVED2017-03-09—AMNEAL PHARMACEUTICALS CO GMBHNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
207692 / 001FINAL_APPROVAL · FINAL_APPROVED2017-10-16—EPIC PHARMA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
203897 / 003FINAL_APPROVAL · FINAL_APPROVED2017-11-02—RISING PHARMA HOLDINGS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
205982 / 003FINAL_APPROVAL · FINAL_APPROVED2018-10-09—EUGIA PHARMA SPECIALITIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 6 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
091108 / 003SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2011-07-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
204910 / 003CAPLIN STERILES LTDFINAL_APPROVAL · FINAL_APPROVED2016-08-17 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
206699 / 003AMNEAL PHARMACEUTICALS CO GMBHFINAL_APPROVAL · FINAL_APPROVED2017-03-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
207692 / 001EPIC PHARMA LLCFINAL_APPROVAL · FINAL_APPROVED2017-10-16 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
203897 / 003RISING PHARMA HOLDINGS INCFINAL_APPROVAL · FINAL_APPROVED2017-11-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
205982 / 003EUGIA PHARMA SPECIALITIES LTDFINAL_APPROVAL · FINAL_APPROVED2018-10-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
REGULATORY_STATUS2026-04-08TERMINAL_STATUSFDA approval of this entire NDA and its strengths was withdrawn effective 2026-04-08. This legal notice supersedes the discontinued-list classification. Rereview corrected Discontinued to WITHDRAWN and recorded the actual FDA effective date. The notice publication date is not substituted for a later effective date.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.